CVR: 45364577
DKK 1,026,737
Revenue
Net result: DKK -1,626,789
Walden Holding ApS, Sophie Holding ApS
1 more
CVR · view ownership and management
Owner registered: Sophie Holding ApS
CVR · 17/10/2025
View the full event history
Akasi Pharma ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2025. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Walden Emil Bjørn-Yoshimoto and Helena Safavi-Hemami. The company is owned by Walden Holding ApS, Sophie Holding ApS and Venimic LLC. In 2025, the company reported revenue of DKK 1,026,737 and a net result of DKK -1,626,789. Equity in the 2025 report amounted to DKK -1,570,789.
Selskabets formål er at udføre forskning, udvikling, produktion og handel med lægemidler, samt at udøve enhver aktivitet, der har direkte eller indirekte forbindelse hermed.
Source: annual reports filed with the Danish Business Authority.
Compared to 1.041 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAkasi Pharma ApS was founded on 29 January 2025.
Akasi Pharma ApS is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (industry code 721000).
Akasi Pharma ApS is owned by Walden Holding ApS, Sophie Holding ApS and Venimic LLC.
In 2025, Akasi Pharma ApS reported revenue of DKK 1,026,737.
The management of Akasi Pharma ApS consists of Walden Emil Bjørn-Yoshimoto and Helena Safavi-Hemami.
Akasi Pharma ApS is located at c/o BioInnovation Institute, Ole Maaløes Vej 3, 2200 København N.
Claim this page to add your logo and social links. Free to get started.
Akasi Pharma ApS has published its annual report for 2025. Revenue came to DKK 1,026,737, and the net result was DKK -1,626,789.
As of October 17, 2025, Sophie Holding ApS is registered as an owner of Akasi Pharma ApS with an ownership share of 10%.
As of October 17, 2025, is registered as an owner of Akasi Pharma ApS with an ownership share of 25%.
As of January 29, 2025, Walden Emil Bjørn-Yoshimoto is registered as director of Akasi Pharma ApS.
As of January 29, 2025, Helena Safavi-Hemami is registered as director of Akasi Pharma ApS.
As of January 29, 2025, Walden Holding ApS is registered as an owner of Akasi Pharma ApS with an ownership share of 50%.
Akasi Pharma ApS was founded on January 29, 2025.
Companies in the same industry and area
CVR 45436497
CVR 46543912
CVR 44478587
CVR 31427169
CVR 43506242
